在转移性结直肠癌中成功进行 cetuximab 再试验:一个病例报告
Alexandra Guedes1, Sandra Silva2, Sandra Custódio2
1Department of Medical Oncology, Centro Hospitalar Gaia/Espinho, Vila Nova de Gaia 4434-502, Portugal. alexandra.pereira.guedes@ulsge.min-saude.pt.
World journal of clinical oncology
|October 1, 2024
概括
挑战转移性结直肠癌 (mCRC) 的患者,这些患者有RAS野生型 (RAS-wt) 瘤,具有表皮生长因子受体 (EGFR) 抑制剂,如 cetuximab,可以在以后的治疗线上有效. 这一策略为延长无进展生存期提供了一个有希望的选择.
科学领域:
- 在瘤学瘤学.
- 胃肠病学 胃肠病学
- 癌症治疗方法 癌症治疗方法
背景情况:
- 转移性结直肠癌 (mCRC) 治疗越来越多地根据瘤生物学来个性化.
- RAS野生型 (RAS-wt) mCRC患者可能受益于重新使用表皮生长因子受体 (EGFR) 抑制剂.
- 循环瘤DNA (ctDNA) 分析正在成为选择患者接受抗EGFR治疗的工具.
更多相关视频
相关概念视频
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...